<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02948842</url>
  </required_header>
  <id_info>
    <org_study_id>CHC</org_study_id>
    <nct_id>NCT02948842</nct_id>
  </id_info>
  <brief_title>Clostridium Histolyticum Collagenase Injection for Urethral Disease</brief_title>
  <official_title>Clostridium Histolyticum Collagenase Injection Treatment for Urethral Disease: a Prospective, Single-center, Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of clostridium histolyticum collagenase
      (XIAFLEX®) in treating urethral strictures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, pilot study to explore the efficacy of clostridium histolyticum
      collagenase (XIAFLEX®) in treating urethral strictures. Subjects will be followed for 2 years
      from the initial drug treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of complication after treatment</measure>
    <time_frame>84 days</time_frame>
    <description>Rate of complication after treatment with clostridium histolyticum collagenase and saline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients needing further intervention for treatment of urethral stricture</measure>
    <time_frame>2 years</time_frame>
    <description>Further intervention - defined as any medical or surgical intervention for treatment of urethral stricture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of recurrence of urethral stricture</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over time during total study period on: American Urology Association questionnaire scores</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to urethral stricture recurrence</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to additional intervention for urethral stricture</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over time during total study period on: obstructive voiding dysfunction</measure>
    <time_frame>2 years</time_frame>
    <description>Obstructive voiding dysfunction defined as change in uroflow and post-void residual measurements</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Urethral Stricture</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo instillation of local anesthesia (20 mL of 2% urethral lidocaine jelly), the patient will undergo cystoscopy, transurethral injection (via a 70 cm 4.8 Fr flexible cystoscopic needle with a 23 gauge needle tip manufactured by Laborie®, Ontario, Canada) of 0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>On day of treatment, patients will undergo instillation of local anesthesia (20 mL of 2% urethral lidocaine jelly), the patient will undergo cystoscopy, transurethral injection (via a 70 cm 4.8 Fr flexible cystoscopic needle with a 23 gauge needle tip manufactured by Laborie®, Ontario, Canada) of 0.08ml of injectable normal saline. The depth and location of the needle will be determined pre-procedurally with urethral ultrasonography with the needle in a semi-parallel manner into the plaque as to avoid perforation into nearby structures. Injections will be performed at a single site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clostridium Histolyticum Collagenase</intervention_name>
    <description>0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>XIAFLEX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.08ml of injectable normal saline</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Injectable normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males

          -  Age ≥ 18 years

          -  Failed prior proven conservative measures, including DVIU or balloon dilation of the
             stricture will be included in this study

          -  Able and willing to undergo regular intervention as well as evaluation as described
             below will be included in the study

          -  With a single stricture &lt;2cm in size that can be identified on retrograde urethrogram
             or voiding cystourethrogram will be included in the study.

          -  Must agree not to participate in a clinical study involving another investigational
             drug or device throughout the duration of this study

          -  Must be competent to understand the information given in IRB approved ICF and must
             sign the form prior to the initiation of any study procedure

        Exclusion Criteria:

          -  Has not yet undergone proven non-invasive measures, including DVIU or balloon
             dilation.

          -  Multiple strictures or a single stricture larger than 2cm in size, measured with
             retrograde urethrogram or voiding cystourethrogram.

          -  Age &lt;18

          -  Females

          -  Prior urethroplasty

          -  Urethral fistula

          -  Allergy or sensitivity to CHC

          -  Bleeding disorder or anticoagulant use other than aspirin up to 150mg/day

          -  Untreated urinary tract infection

          -  Inability to perform intermittent self-catheterization

          -  Participation in another clinical study or treatment with an investigational drug or
             device

          -  Serious or active medical or psychiatric condition which, in the opinion of the
             Investigator, may interfere with treatment, assessment, or compliance with the
             protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucas R Wiegand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thanh Tran, BS</last_name>
    <phone>813-844-8544</phone>
    <email>thanhtran@health.usf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Karlnoski, PhD</last_name>
    <phone>83-844-4133</phone>
    <email>rkarlnos@health.usf.edu</email>
  </overall_contact_backup>
  <link>
    <url>http://www.endo.com/File%20Library/Products/Prescribing%20Information/Xiaflex_prescribing_information.html</url>
    <description>XIAFLEX® [package insert]</description>
  </link>
  <results_reference>
    <citation>Santucci RA, Joyce GF, Wise M. Male urethral stricture disease. J Urol. 2007 May;177(5):1667-74.</citation>
    <PMID>17437780</PMID>
  </results_reference>
  <results_reference>
    <citation>Chenoweth CE, Saint S. Urinary tract infections. Infect Dis Clin North Am. 2011 Mar;25(1):103-15. doi: 10.1016/j.idc.2010.11.005. Epub 2010 Dec 18. Review.</citation>
    <PMID>21315996</PMID>
  </results_reference>
  <results_reference>
    <citation>Heyns CF, Steenkamp JW, De Kock ML, Whitaker P. Treatment of male urethral strictures: is repeated dilation or internal urethrotomy useful? J Urol. 1998 Aug;160(2):356-8.</citation>
    <PMID>9679876</PMID>
  </results_reference>
  <results_reference>
    <citation>Hussain M, Greenwell TJ, Shah J, Mundy A. Long-term results of a self-expanding wallstent in the treatment of urethral stricture. BJU Int. 2004 Nov;94(7):1037-9.</citation>
    <PMID>15541123</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang K, Qi E, Zhang Y, Sa Y, Fu Q. Efficacy and safety of local steroids for urethra strictures: a systematic review and meta-analysis. J Endourol. 2014 Aug;28(8):962-8. doi: 10.1089/end.2014.0090. Epub 2014 Jun 3. Review.</citation>
    <PMID>24745607</PMID>
  </results_reference>
  <results_reference>
    <citation>Peak TC, Mitchell GC, Yafi FA, Hellstrom WJ. Role of collagenase clostridium histolyticum in Peyronie's disease. Biologics. 2015 Sep 29;9:107-16. doi: 10.2147/BTT.S65619. eCollection 2015. Review.</citation>
    <PMID>26491251</PMID>
  </results_reference>
  <results_reference>
    <citation>Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC 3rd. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013 Jul;190(1):199-207. doi: 10.1016/j.juro.2013.01.087. Epub 2013 Jan 31. Review.</citation>
    <PMID>23376148</PMID>
  </results_reference>
  <results_reference>
    <citation>Cavalcanti AG, Costa WS, Baskin LS, McAninch JA, Sampaio FJ. A morphometric analysis of bulbar urethral strictures. BJU Int. 2007 Aug;100(2):397-402.</citation>
    <PMID>17617144</PMID>
  </results_reference>
  <results_reference>
    <citation>Sangkum P, Yafi FA, Kim H, Bouljihad M, Ranjan M, Datta A, Mandava SH, Sikka SC, Abdel-Mageed AB, Moparty K, Hellstrom WJ. Collagenase Clostridium histolyticum (Xiaflex) for the Treatment of Urethral Stricture Disease in a Rat Model of Urethral Fibrosis. Urology. 2015 Sep;86(3):647.e1-6. doi: 10.1016/j.urology.2015.06.013. Epub 2015 Jun 27.</citation>
    <PMID>26126692</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urethral Stricture</mesh_term>
    <mesh_term>Urethral Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

